InflaRx develops drugs that block the inflammatory protein C5a, with vilobelimab sold to hospitals for COVID-19 patients. IFRX reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 14 | Needham | Initiated | Buy | |
| Aug 7 | Cantor Fitzgerald | Maintained | Buy | |
| May 13 | Raymond James | Upgrade | Buy |
Seasonality
How IFRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in IFRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IFRX is in one of them and how their past IFRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IFRX in an article yet. Here's the latest on the wider market.
About InflaRx N.V.
InflaRx is a biopharmaceutical company based in Jena, Germany, that develops treatments aimed at blocking C5a, a protein that drives inflammation. Its approved product, vilobelimab, is given intravenously and is sold in the U.S. under the name GOHIBIC, where hospitals can order it for critically ill COVID-19 patients. Its lead candidate, izicopan, is taken by mouth and is being studied for chronic skin conditions such as hidradenitis suppurativa and chronic spontaneous urticaria.
- Headquarters
- Jena, Germany